To further assess the impact of BTKi on short-term T cell functional responses, a 24-h cytokine release assay demonstrated that in vitro treatment with ibrutinib significantly reduced IL-2 and IFNγ secretion by CLL patient PBMC (Fig. 3C). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.